Endometrial Cancer Treatment Global Market Report 2024

The endometrial cancer treatment market has grown strongly in recent years. It will grow from $29.9 billion in 2023 to $31.41 billion in 2024 at a compound annual growth rate (CAGR) of 5.0%. The growth witnessed in the historical period can be ascribed to demographic trends, advancements in diagnostic tools, treatment guidelines, and protocols, increased awareness, and screening programs, along with the evolution of healthcare infrastructure.

The endometrial cancer treatment market is expected to see strong growth in the next few years. It will grow to $38.96 billion in 2028 at a compound annual growth rate (CAGR) of 5.5%. The anticipated growth in the forecast period can be attributed to the increasing incidence of endometrial cancer, the adoption of personalized medicine approaches, advancements in immunotherapy, the expansion of targeted therapies, and government initiatives and funding. Major trends expected in the forecast period include the development of hormone therapies, the integration of artificial intelligence (AI) in treatment planning, exploration of novel chemotherapeutic agents, improved supportive care, and an increase in clinical trials for emerging therapies.

The anticipated growth of the endometrial cancer treatment market is expected to be driven by the growing prevalence of endometrial cancer. The term "prevalence of endometrial cancer" denotes the increasing number of cases of endometrial cancer within a specific population or over a certain period. This surge is attributed to changes in risk factors, improved detection and diagnosis methods, increased awareness, and an aging population. Endometrial cancer treatments play a crucial role in early detection, offering targeted therapies, preventing recurrence, and contributing to clinical trials and research studies to enhance treatment options. With the continuous rise in the prevalence of endometrial cancer and ongoing advancements in treatment options, the endometrial cancer treatment market is poised for growth. As an illustration, Cancer.Net estimates that around 66,200 people in the United States will be diagnosed with uterine or endometrial cancer in 2023. Hence, the increasing prevalence of endometrial cancer is a key driver of the endometrial cancer treatment market.

The emphasis on personalized medicine is set to fuel the growth of the endometrial cancer treatment market. Personalized medicine involves tailoring medication to prevent, detect, or treat diseases based on an individual's genetic or protein-related information. In the context of endometrial cancer treatment, personalized medicine utilizes genomic profiling to analyze the genetic composition of tumors. This approach facilitates the identification of specific mutations, alterations, or biomarkers that guide treatment decisions. Notably, the US Food and Drug Administration (FDA) approved 12 personalized medicines, constituting approximately 34% of all newly approved therapeutic molecular entities in 2022, according to the Personalized Medicine Coalition. Therefore, the increasing focus on personalized medicine serves as a significant driver for the growth of the endometrial cancer treatment market.

Technological advancements in endometrial cancer diagnosis and treatment are a key trend gaining popularity in the endometrial cancer treatment market. Companies operating in the market are launching technologically advanced endometrial cancer diagnoses and treatments to sustain their position in the market. For instance, in April 2022, Roche Holding AG received FDA approval for VENTANA MMR RxDx Panel endometrial cancer diagnostic kit to diagnose patients eligible for anti-PD1 immunotherapy that is treatment with JEMPERLI (dostarlimab-gxly) monotherapy. This test is an effective tool for clinicians for patient diagnosis and providing new treatment options to women having MMR-deficient endometrial cancer during or after chemotherapy treatment.

Major companies operating in endometrial cancer treatment are focused on introducing innovative solutions such as Jemperli to sustain their position in the market. Jemperli is a programmed death receptor-1 (PD-1) inhibitor used in the field of oncology, particularly for the treatment of certain types of cancer. For instance, in April 2021, the US Food and Drug Administration, a US-based federal agency, granted accelerated approval to Jemperli (dostarlimab) for treating patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR (which contain abnormalities that affect the proper repair of DNA inside the cell).

In November 2021, Inspirna a US-based clinical-stage biopharmaceutical company developing drugs for cancer treatments announced a collaboration with Bristol Myers Squibb Company for the clinical trial of combination therapy for metastatic endometrial cancer treatment. This collaboration includes the use of RGX-104 (abequolixron) against Liver X Receptor/Apolipoprotein E (“LXR/APOE”) pathway, and Yervoy (ipilimumab). According to this agreement, Bristol Myers Squibb will be providing ipilimumab for the investigating combination therapy and Inspirna will be sponsoring the study and responsible for study cost. Bristol Myers Squibb Company is a US-based pharmaceutical company.

Major companies operating in the endometrial cancer treatment market report are Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Siemens Healthcare AG, Merck & Co. Inc., Sanofi-Aventis, Ariad Pharmaceuticals Inc., Becton Dickinson And Company, Teva Pharmaceutical Industries Limited, AstraZeneca plc, Pfizer Inc., Bristol-Myers Squibb Company, Celgene Corp., Eisai Co. Ltd., AbbVie Inc., Roche Holding AG, Janssen Biotech Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Bayer AG, Eli Lilly and Company, Varian Medical Systems Inc., Regeneron Pharmaceuticals Inc., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc., Stemline Therapeutics Inc., Syros Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Novocure Ltd.

North America was the largest region in the endometrial cancer treatment market in 2023. Asia-pacific is expected to be the fastest-growing region in the global endometrial cancer treatment market report during the forecast period. The regions covered in the endometrial cancer treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the endometrial cancer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main types of endometrial cancer include adenocarcinoma, uterine carcinosarcoma, squamous cell carcinoma, small cell carcinoma, transitional carcinoma, serous carcinoma, and other types. Adenocarcinoma refers to a type of cancer that originates in the glandular cells of a particular organ or tissue in the body. The treatment for endometrial cancer, specifically adenocarcinoma, involves various approaches such as surgery, radiation therapy, chemotherapy, hormonal therapy, targeted therapy, or a combination of these methods. Diagnosing endometrial cancer may include procedures such as biopsy, pelvic ultrasound, hysteroscopy, CT scan, and other diagnostic methods. The endometrial cancer treatments can be administered orally or intravenously, and they are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The endometrial cancer treatment market research report provides endometrial cancer treatment market statistics, including endometrial cancer treatment industry global market size, regional shares, competitors with an endometrial cancer treatment market share, detailed endometrial cancer treatment market segments, market trends and opportunities, and any further data you may need to thrive in the endometrial cancer treatment industry. This endometrial cancer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The endometrial treatment market includes revenues earned by entities by providing drugs, medications, diagnostic devices, radiation therapy equipment, surgical instruments, and devices. Therapies that are used in the treatment of endometrial cancer. The endometrial treatment market includes surgery, radiation therapy, chemotherapy, hormonal therapy, targeted therapy, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.